S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
Log in
NASDAQ:KALA

Kala Pharmaceuticals Stock Forecast, Price & News

$9.83
+1.09 (+12.47 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.88
Now: $9.83
$9.83
50-Day Range
$7.96
MA: $8.77
$9.33
52-Week Range
$3.24
Now: $9.83
$14.68
Volume2.14 million shs
Average Volume1.13 million shs
Market Capitalization$551.07 million
P/E RatioN/A
Dividend YieldN/A
Beta0.24
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Read More
Kala Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.07 million
Book Value$0.86 per share

Profitability

Net Income$-94,350,000.00
Net Margins-1,993.41%

Miscellaneous

Employees136
Market Cap$551.07 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$9.83
+1.09 (+12.47 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

How has Kala Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, KALA shares have increased by 28.8% and is now trading at $9.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Kala Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kala Pharmaceuticals
.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Kala Pharmaceuticals
.

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.42) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.42). The business had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.76 million. Kala Pharmaceuticals had a negative return on equity of 105.36% and a negative net margin of 1,993.41%.
View Kala Pharmaceuticals' earnings history
.

What price target have analysts set for KALA?

7 equities research analysts have issued 1-year price objectives for Kala Pharmaceuticals' shares. Their forecasts range from $10.00 to $39.00. On average, they expect Kala Pharmaceuticals' stock price to reach $19.71 in the next year. This suggests a possible upside of 100.6% from the stock's current price.
View analysts' price targets for Kala Pharmaceuticals
.

Are investors shorting Kala Pharmaceuticals?

Kala Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 5,800,000 shares, an increase of 35.2% from the August 15th total of 4,290,000 shares. Based on an average trading volume of 897,600 shares, the days-to-cover ratio is presently 6.5 days.
View Kala Pharmaceuticals' Short Interest
.

Who are some of Kala Pharmaceuticals' key competitors?

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Bristol-Myers Squibb (BMY), Micron Technology (MU), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Amarin (AMRN), Alibaba Group (BABA) and VBI Vaccines (VBIV).

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the following people:
  • Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 54, Pay $871.14k)
  • Mr. Todd Bazemore, Chief Operating Officer (Age 50, Pay $607.5k)
  • Mr. Eric L. Trachtenberg, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $646.56k)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 45)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (8.35%), Vanguard Group Inc. (3.93%), Sofinnova Investments Inc. (0.90%), Bank of America Corp DE (0.71%), Opaleye Management Inc. (0.64%) and Assenagon Asset Management S.A. (0.65%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah and Todd Bazemore.
View institutional ownership trends for Kala Pharmaceuticals
.

Which institutional investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Alyeska Investment Group L.P., Goldman Sachs Group Inc., Matisse Capital, Tudor Investment Corp Et Al, Lindbrook Capital LLC, Wedbush Securities Inc., and UBS Group AG.
View insider buying and selling activity for Kala Pharmaceuticals
.

Which institutional investors are buying Kala Pharmaceuticals stock?

KALA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Assenagon Asset Management S.A., Vanguard Group Inc., Federated Hermes Inc., Barclays PLC, Sofinnova Investments Inc., Ensign Peak Advisors Inc, and Nuveen Asset Management LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah, and Todd Bazemore.
View insider buying and selling activity for Kala Pharmaceuticals
.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $9.83.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $551.07 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 136 workers across the globe.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is www.kalarx.com.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.